Company Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities.
The company was founded in 2018 and is based in Carmel, Indiana.
| Country | United States |
| Founded | 36 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Peter Hawryluk |
Contact Details
Address: 11711 N. Meridian Street, Suite 300 Carmel, Indiana 46032 United States | |
| Phone | (317) 659-0200 |
| Website | mbxbio.com |
Stock Details
| Ticker Symbol | MBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001776111 |
| ISIN Number | US55287L1017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| P. Kent Hawryluk | President, Chief Executive Officer and Director |
| Salomon Azoulay, M.D. | Chief Medical Officer |
| Richard Bartram | Chief Financial Officer |
| Tiba Aynechi, Ph.D. | Director |
| James M. Cornelius | Director |
| Carl Gordon, Ph.D. | Director |
| Patrick Heron | Director |
| Edward T. Mathers | Director |
| Ora Pescovitz, M.D. | Director |
| Steven Ryder, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 16, 2024 | 8-K | Current Report |
| Sep 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 13, 2024 | 424B5 | Filing |
| Sep 12, 2024 | EFFECT | Notice of Effectiveness |